TYPE OF SUPPORT
Background
Sugammadex is widely used to reverse neuromuscular blockade and offers clear clinical advantages over traditional agents such as Neostigmine. However, rare adverse events like perioperative hypersensitivity remain difficult to diagnose and quantify. Accurate estimation of incidence and improved diagnostic clarity are essential to support safe clinical use and inform perioperative care.
QCIF Role
Dr Farah Zahir, Head of QCIF Statistics, collaborated with Dr Danielle Crimmins, Consultant Anaesthetist at the Princess Alexandra Hospital in Brisbane, to design and implement the statistical analysis workflow for a multicentre retrospective study.
The study analysed cases of sugammadex hypersensitivity identified through specialist perioperative allergy clinics across South‑East Queensland and Northern New South Wales, Australia, over a 13‑year period.
Cases were defined based on positive intradermal testing (IDT) or skin prick testing (SPT). The study examined clinical presentation, diagnostic pathways, and hypersensitivity reactions to sugammadex and neuromuscular blocking agent mixtures. Incidence rates were estimated in a large cohort of patients exposed to sugammadex using robust statistical methods.
Statistical support included estimation of rare‑event incidence using the Clopper–Pearson method, ensuring accurate and appropriately conservative confidence intervals for low‑frequency outcomes.
Outcome & Impact
This multicentre study identified 30 cases of sugammadex hypersensitivity, most of which were moderate or severe, with rapid onset and hypotension as the predominant clinical feature.
Among an estimated 239,341 exposed patients, confirmed hypersensitivity was rare, with an incidence of 0.004% and life‑threatening reactions occurring in fewer than 0.002% of cases.
These findings provide one of the largest Australian incidence estimates of sugammadex hypersensitivity, supporting its continued safe use while equipping clinicians with robust, evidence‑based data for diagnosis, risk communication, and perioperative decision‑making.
Publication:
The statistical support from QCIF provided clear guidance on data handling, test selection, and reporting. The rigorous approach underpinned the reliability of the study and supported successful publication.
Danielle Crimmins, Consultant Anaesthetist at the Princess Alexandra Hospital in Brisbane
